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The cause of Parkinson disease (PD) is still unknown, but genetic factors have recently been implicated in the
etiology of the disease. So far, four loci responsible for autosomal dominant PD have been identified. Autosomal
recessive juvenile parkinsonism (ARJP) is a clinically and genetically distinct entity; typical PD features are associated
with early onset, sustained response to levodopa, and early occurrence of levodopa-induced dyskinesias, which are
often severe. To date, only one ARJP gene, Parkin, has been identified, and multiple mutations have been detected
both in families with autosomal recessive parkinsonism and in sporadic cases. The Parkin-associated phenotype is
broad, and some cases are indistinguishable from idiopathic PD. In 50% of families with ARJP that have been
analyzed, no mutations could be detected in the Parkin gene. We identified a large Sicilian family with four definitely
affected members (the Marsala kindred). The phenotype was characterized by early-onset (range 32–48 years)
parkinsonism, with slow progression and sustained response to levodopa. Linkage of the disease to the Parkin gene
was excluded. A genomewide homozygosity screen was performed in the family. Linkage analysis and haplotype
construction allowed identification of a single region of homozygosity shared by all the affected members, spanning
12.5 cM on the short arm of chromosome 1. This region contains a novel locus for autosomal recessive early-
onset parkinsonism, PARK6. A maximum LOD score 4.01 at recombination fraction .00 was obtained for marker
D1S199.
Introduction
Parkinson disease (PD [MIM 168600]) is a common
neurodegenerative disorder that usually occurs later in
life, presenting with bradykinesia, resting tremor, mus-
cular rigidity, and postural instability, with sustained re-
sponse to levodopa. The pathological hallmarks are the
occurrence of Lewy bodies (cytoplasmic eosinophilic in-
clusions) and neuronal loss, which affects the substan-
tia nigra pars compacta (SNpc) extensively and other
regions of the brain less specifically (Fearnley and Lees
1991). A genetic contribution to the etiology of PD is
now well established and appears to be particularly im-
portant in cases with early onset of the disease (Tanner
et al. 1999). The gene a-synuclein (Polymeropoulos et
al. 1997) has been proved in families with autosomal
dominant PD, and a second gene, that for ubiquitin car-
boxy-terminal hydrolase L1, has been implicated in dis-
ease causation (Leroy et al. 1998). Moreover, two other
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genetic loci have been mapped: PARK3 on chromosome
2p13 and PARK4 on chromosome 4p14-16.3 (Gasser
et al. 1998; Farrer et al. 1999). However, autosomal
dominant forms are rare and seem to account for only
a small number of families. Autosomal recessive juve-
nile parkinsonism (ARJP [MIM 600116]) is a distinct
clinical and genetic entity within familial PD; it is char-
acterized by typical PD features associated with early
age at onset (!40 years), slow progression of the disease,
sustained response to levodopa, early levodopa-induced
complications (fluctuations and dyskinesias) that are of-
ten severe, hyperreflexia, and mild dystonia mainly in
the feet (Yamamura et al. 1973; Ishikawa and Tsuji
1996). Pathological studies have demonstrated a highly
selective degeneration of dopaminergic neurons in the
SNpc and the locus coeruleus and an absence of Lewy
bodies (Takahashi et al. 1994). ARJP was initially de-
scribed in Japanese patients (Yamamura et al. 1973).
Recently, Matsumine and coworkers (1997) identified a
novel gene, Parkin, located on chromosome 6q25.2-27
(Kitada et al. 1998). A wide variety of mutations have
been detected in families with autosomal recessive par-
kinsonism and in sporadic cases of different ethnic origin
(Hattori et al. 1998; Leroy et al. 1998; Abbas et al. 1999;
Nisipeanu et al. 1999; Lu¨cking et al. 2000). The inclu-
sion criteria adopted in these studies were age at onset
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45 years (in at least one affected member of the family,
for familial cases) and unaffected parents. It has been
proved that, especially in non-Japanese cases, mutations
in the Parkin gene are associated with a wide range in
both age at onset (64 years) and clinical signs, and
they can result in parkinsonism that is clinically indis-
tinguishable from PD, making genotype-phenotype cor-
relation uncertain (Abbas et al. 1999; Klein et al. 2000).
Nevertheless, only ∼50% of cases of autosomal recessive
early-onset parkinsonism are related to the Parkin gene,
and in most patients, especially sporadic cases, the con-
tribution of genetic factors remains to be elucidated
(Lu¨cking et al. 2000). It is likely that a novel, as yet
unidentified, gene is responsible for early-onset parkin-
sonism in some of these cases. We mapped a novel locus,
named “PARK6,” to a 12.5-cM region on chromosome
1p35-36, in a large Italian family with autosomal re-
cessive early-onset parkinsonism, confirming the genetic
heterogeneity of this disorder.
Subjects and Methods
Subjects
A large Italian family (the Marsala kindred) compris-
ing 122 members was investigated. The methodology
and the clinical characterization of the family have been
reported elsewhere (Valente et al. 1999). We examined
35 subjects, including 30 family members and 5 spouses.
After informed consent was obtained, venous-blood
samples were taken from 27 family members and the 5
spouses, for DNA analysis.
DNA and Linkage Analysis
DNA was extracted from leukocytes, by standard
techniques. Exclusion of linkage between the disease and
PARK2 on chromosome 6q has been reported elsewhere
(Valente et al. 1999). A simulation study performedwith
the program SLINK (Ott 1989) revealed a maximum
expected LOD score of 4.2 at recombination fraction (v)
.00. The family was then considered suitable for a ge-
nomewide homozygosity mapping (Lander and Botstein
1987). In the first screen, only the four definitely affected
individuals were genotyped. We analyzed 400 highly
polymorphic fluorescent microsatellite markers span-
ning the 22 autosomes and having an average distance
of 10 cM (Linkage Mapping Set version 2; Applied Bio-
systems). Microsatellite markers were amplified from ge-
nomic DNA by the PCR technique, as specified by the
manufacturers, and were electrophoresed on a denatur-
ing acrylamide gel by a 377 XLDNA sequencer (Applied
Biosystems). DNA fragment-size analysis was performed
semiautomatically by GENESCAN and GENOTYPER
software (Applied Biosystems), to determine genotypes.
When all the affected individuals were shown to be
homozygous for the same allele at a given marker, the
surrounding region was saturated with closely spaced
microsatellite markers. All the available family members
were then genotyped, and haplotypes were constructed
manually. Phase was assigned on the basis of the min-
imum number of recombinants.
Two-point LOD scores were generated using the
FASTLINK version of the MLINK program (Cot-
tingham et al. 1993; Dwarkadas et al. 1994), an as-
sumption of equal recombination rate for the two sexes,
autosomal recessive inheritance, reduced penetrance
(.90), gene frequency .001, and equal allele frequencies
for each marker. Loops were broken by the automated
loop-breaking procedure described by Becker and co-
workers (1998). Marker order and genetic distances
were based on the chromosome 1 genetic map of the
Center for Medical Genetics, Marshfield Medical Re-
search Foundation, and on the chromosome 1 physical
map of the National Center for Biotechnology Infor-
mation, available at The Human Genome website.
Results
Clinical Analysis
A simplified pedigree of the family is shown in fig-
ure 1. The age at onset in affected subjects was 32–48
years. The patients presented with the typical parkin-
sonian phenotype, including slow progression of the dis-
ease, sustained response to levodopa, and occurrence of
levodopa-associated dyskinesias of variable severity.
Foot dystonia and sleep benefit were not observed. No
pathological data are available.
Both the high frequency of consanguineous marriages
within the family and the presence of affected members
of both sexes in only one generation strongly suggest an
autosomal recessive mode of inheritance. Moreover, ge-
nealogic records permitted us to trace the origin of the
family to a common ancestral couple seven generations
back (18th century). A summary of the clinical presen-
tation in the family and of the Hoehn and Yahr (1967)
stage (on-state) are given in table 1.
Homozygosity Mapping and Linkage Analysis
Linkage to PARK2 has been excluded by a previous
study (Valente et al. 1999). Given the autosomal reces-
sive pattern of inheritance, we expected homozygosity
at the level of the disease locus in affected individuals,
owing to identity by descent from a common progenitor
(Lander and Botstein 1987). In the four definitely af-
fected family members, 400 microsatellite markers cov-
ering all autosomes were analyzed. These individuals
were homozygous for the same allele at seven marker
loci, located on chromosomes 1, 8, 10, 14, and 19. The
regions surrounding these seven loci and all regions sur-
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Figure 1 Simplified pedigree of the family, and haplotypes of marker loci spanning the linked region on chromosome 1p35-36. Black
symbols denote definitely affected individuals, and deceased members are denoted by a diagonal bar. A short thin horizontal bar above a symbol
indicates a family member who was examined clinically. The black bar denotes the disease-associated haplotype. To protect patient confidentiality,
a diamond symbol has been used to mask the sex of some unaffected individuals.
rounding noninformative markers were saturated with
closely spaced microsatellite markers. All available fam-
ily members were genotyped, and haplotypes were con-
structed. A combination of negative LOD scores and the
detection of different haplotypes carried by the affected
individuals allowed exclusion of all the autosomes, ex-
cept for a region on the short arm of chromosome 1.
All markers spanning this candidate interval produced
positive LOD scores, with a maximum LOD score of
4.01 (vp .00), between the disease and markerD1S199
(table 2). Calculation of pairwise LOD scores under dif-
ferent penetrance values and under the assumption of
affected individuals–only analysis did not result in a sig-
nificant change (data not shown). All affected individ-
uals in the family shared a region of homozygosity, be-
tween D1S199 and D1S2885 (fig. 1), allowing the
identification of a 12.5-cM interval containing a novel
gene (i.e., PARK6) for autosomal recessive parkinson-
ism. The upper and lower extents of the region are de-
termined by recombinations occurring between markers
D1S483 and D1S199 (telomeric end) and between
markers D1S2885 and D1S247 (centromeric end), re-
spectively, which were detected in subjects VI:7, VI:9,
and VI:17.
Discussion
We have identified, by homozygosity mapping, a second
locus for autosomal recessive early-onset parkinsonism,
a locus named “PARK6,” on the short arm of chro-
mosome 1 in a family from Sicily. The phenotype is
characterized by early-onset parkinsonism with slow
progression, sustained response to levodopa, and fre-
quent levodopa-induced fluctuations and dyskinesias.
Other signs often reported in ARJP, such as dystonia at
onset and sleep benefit, are absent. The clinical picture
in this family overlaps with that described in Parkin-
positive families of non-Japanese origin (Abbas et al.
1999). Lu¨cking and coworkers screened 73 families with
onset age45 years in at least one affected member and
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Table 1
Clinical Phenotype in Four Individuals with PD
PATIENT CHARACTERISTICS
STATUS OF AFFECTED
FAMILY MEMBERa
VI:7 VI:9 VI:17 VI:23
Sex M M M F
Age at onset (years) 45 48 32 38
Asymmetry at onset? Yes No Yes Yes
Disease duration (years) 29 20 20 7
Levodopa-induced dyskinesias    
Phenotype at examination:
Resting tremor 81  69 68
Bradykinesia 0 77 0 0
Rigidity 0 0 0 0
Postural instability 0 0 0 -
Hoehn and Yahr (1967)
stage (on-state) II.5 II.5 III II
Daily medication:
Levodopa (mg) 300 625 800 500
Pergolide (mg) 4 … 3 …
a  p Mild;  p moderate;  p severe;  p
uncertain.
Table 2
Pairwise LOD Scores for PD and Markers on Chromosome 1p
MARKER
LOD SCORES AT v p
.0 .01 .05 .1 .2 .3 .4
D1S483 .18 .53 .83 .83 .59 .31 .10
D1S199 4.01 3.92 3.55 3.08 2.14 1.24 .48
D1S2732 2.65 2.60 2.39 2.10 1.46 .83 .32
D1S2828 3.49 3.42 3.12 2.72 1.89 1.08 .41
D1S478 3.45 3.36 3.03 2.61 1.78 1.00 .38
D1S2702 3.36 3.16 2.84 2.44 1.65 .93 .36
D1S2734 3.62 3.55 3.26 2.87 2.03 1.19 .46
D1S2674 3.29 3.21 2.87 2.44 1.60 .87 .32
D1S2885 3.94 3.85 3.49 3.03 2.11 1.23 .49
D1S247 1.01 1.35 1.59 1.48 1.03 .58 .19
100 sporadic cases with onset age 45 years (Lu¨cking
2000). They found Parkin mutations in approximately
half of the families, but in only 18/100 sporadic cases,
most (14/18) with onset age 20 years. The typical
ARJP features—such as dystonia, hyperreflexia, sus-
tained response to levodopa, and early levodopa-induced
dyskinesias—were more frequent in the Parkin-positive
patients than in the Parkin-negative group. However,
these signs were less frequent than in previous reports,
and none could be used to specifically distinguish be-
tween the two groups. The age at onset in the Parkin-
positive group was, on average, lower than that in the
Parkin-negative group, but mutations were identified in
patients with onset age 45 years (64 years) and with
clinical features difficult to distinguish from those of PD
(Klein et al. 2000; Lu¨cking et al. 2000).
The identification of several families that have auto-
somal recessive parkinsonism but that do not have Par-
kin mutations and are clinically indistinguishable from
the Parkin-positive families strongly suggests the exis-
tence of at least one other, possibly similar, gene re-
sponsible for autosomal recessive parkinsonism. The
identification of a novel locus for autosomal recessive
early-onset parkinsonism in a family with a phenotype
similar to that reported for Parkin is a crucial step to-
ward the identification of another gene that could ac-
count for at least a subset of the Parkin-negative cases.
It is noteworthy that the disease in this family is more
characteristic of sporadic, Lewy-body PD, since it has
both a later onset age than is seen in Parkin-positive
patients and fewer atypical features. Still, the absence
of autoptic confirmation does not allow us to assign a
definite diagnosis of PD. The term “early-onset parkin-
sonism” is preferred in the case of families, such as those
studied in the present article, for which information on
the occurrence of Lewy bodies and on the pattern of
neuronal loss is missing.
The role of this novel locus needs to be tested in other
autosomal recessive Parkin-negative families and in
cases of early-onset sporadic parkinsonism, since a spo-
radic presentation may underlie an autosomal recessive
mode of inheritance. Until the PARK6 gene has been
identified, a screen will be possible only by a search of
regions of homozygosity within the candidate interval.
Homozygosity mapping is a powerful technique to map
genes responsible for autosomal recessive diseases in
either consanguineous or nonconsanguineous pedigrees
(Wang et al. 1997). However, this method is not com-
pletely accurate in determining the frequency of a gene.
It is worth noting that individual V:10 shares with
the affected individuals a smaller region of homozy-
gosity, from D1S2674 to D1S247. At the latest exam-
ination, this individual was 84 years old and did not
show any signs of PD. It is likely that the gene is located
outside the region of homozygosity shared by the un-
affected person. In this case, the linked interval would
be reduced to a 9-cM region between D1S483 and
D1S2674. Alternatively, the identification of a definitely
unaffected family member partially sharing the region
of homozygosity can be explained if a reduced pene-
trance of the underlying gene is assumed. This would
be in agreement with the reduced (.9) penetrance of the
Parkin gene, and, in fact, we used this penetrance value
for linkage calculations in this family. This issue will be
clarified by detection of recombinations in affected in-
dividuals from other families.
The Parkin protein appears to be involved in protein
degradation, as a ubiquitin-protein ligase interacting
with the ubiquitin-conjugating enzyme UbcH7 (Shi-
mura et al. 2000). The protein is abundant in the mel-
anin-containing neurons of SNpc in normal individuals
and in cases of sporadic parkinsonism, where it is also
detected in association with a-synuclein within Lewy
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bodies. Conversely, mutations in the Parkin gene com-
pletely abolish the expression of the Parkin protein,
which is not detectable in any region of patients’ brains
(Shimura et al. 1999). The mechanism of selective neu-
ral cell death remains to be clarified; however, it is likely
that the absence of Parkin protein results in accumu-
lation of still-unidentified proteins leading to selective
neuronal degeneration.
The work of the human genome–sequencing project
has resulted in availability of a draft sequence of much
of the genome, including the 12.5-cM region that we
have identified on chromosome 1. This region, which
is equivalent to ∼10.5 Mb on physical maps of the re-
gion, contains a large number of genes, both predicted
and already known. Included in this group are a number
of homeobox genes and the genes for endothelin-con-
verting enzyme 1 and a G-protein–coupled receptor.
However, none of them either presents similarities with
Parkin or represents an obvious candidate for PD. The
identification of other families with linkage to chro-
mosome 1p will help in refinement of the locus position
on the genetic map, which is an essential step toward
the identification of the gene and its function.
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